93 results about "Galactosyltransferase" patented technology

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

A novel UDP-Gal regeneration process and its combined use with a galactosyltransferase to add galactose to a suitable acceptor substrate. Also described herein are synthetic methods for generating Globo-series oligosaccharides in large scale, wherein the methods may involve the combination of a glycosyltransferase reaction and a nucleotide sugar regeneration process.

The invention relates to the genetic manipulation of non-human animals. More particularly, the invention relates to genetic manipulation of non-human animals to be used for xenotransplantation. The invention provides viable gene knockout swine including swine in which the α(1,3)-galactosyltransferase gene has been disrupted, methods for making such swine, and methods of using the tissues and organs of such swine for xenotransplantation.

The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.

The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with post-translational glycosylations. The methods can be used to detect O-GlcNAc post-translational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engineered mutant of β-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.

The invention relates to the genetic manipulation of non-human animals. More particularly, the invention relates to genetic manipulation of non-human animals to be used for xenotransplantation. The invention provides a method of selecting GGTA 1 null cells, a viable GGTA 1 null swine, methods for making such swine, and methods of using cells, tissues and organs of such swine for xenotransplantation.

The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.

The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.

The invention discloses a method for modifying flavonoid glycoside compounds with galactosy transferase. The flavonoid glycoside compounds are ubiquitous secondary metabolites in the nature and one of main active ingredients of medicinal plant, and have physiological activities of antibacterium, cancer resistance, antioxidation and the like. However, natural flavonoid glycoside compounds frequently have the defects of poor water solubility, poor drug effect and the like. The method solves the defects of relatively low solubility of the natural flavonoid glycoside compounds and takes the natural flavonoid glycoside compounds as a forerunner to improve the water solubility thereof by a glycosylation reaction, thereby improving the bioavailability thereof. The technical essential of the method is as follows: an enzymatic reaction is applied to the synthesis of polyglycoside of flavonoid compounds. Compared with chemical synthesis methods, the method has higher synthesis efficiency and lower cost. After glycosylation modification, part of drugs can improve drug effect and reduce toxic side effect; therefore, the method provides a new approach for the development of new drugs of the flavonoid compounds.

The present invention discloses that an intratumoral injection of: i) glycolipids with α-gal epitope; ii) gene vectors comprising an α1,3galactosyltransferase gene; or iii) a mixture of α1,3galactosyltransferase, neuraminidase, and uridine diphosphate galactose results in tumor regression and / or destruction. Binding of the natural anti-Gal antibody to de novo expressed tumoral α-gal epitopes induces inflammation resulting in an anti-Gal antibody mediated opsonization of tumor cells and their uptake by antigen presenting cells. These antigen presenting cells migrate to draining lymph nodes and activate tumor specific T cells thereby converting the treated tumor lesions into in situ autologous tumor vaccines. This therapy can be applied to patients with multiple lesions and in neo-adjuvant therapy to patients before tumor resection. In addition to the regression and / or destruction of the treated tumor, such a vaccine will help in the immune mediated destruction of micrometastases that are not detectable during the removal of the treated tumor.

The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (αGT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.

The invention provides an article of manufacture comprising a substantially non-immunogenic xenograft for implantation into humans. The xenograft is a body part dissected from a transgenic 1,3-α-galactosyltransferase gene-deficient animal, wherein the cells of the body part are dead. The invention also provides methods for preparing a xenograft by removing a body part from a transgenic animal, which is 1,3-α-galactosyltransferase gene-deficient, to provide a xenograft; optionally washing the xenograft in saline and alcohol; subjecting the xenograft to a cellular disruption treatment; optionally treating the xenograft with crosslinking agents, and optionally treating the xenograft with a proteoglycan-depleting factor. The invention further provides a method for sterilizing xenograft material, having the steps of obtaining substantially non-immunogenic xenograft material; treating the xenograft material with at least one crosslinking agent; and subjecting the crosslinked xenograft material to a radiation treatment.

The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galacto-syltransferase and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation. The invention additionally provides nucleic acid molecules and expression vectors of non-mammalian β-1,4-galactosyltransferases.

The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.

The present invention provides a recombinant expression cassette comprising an α1-3 galactosyltransferase promoter operably linked to a polynucleotide for expression. The invention also provides a recombinant mutating cassette comprising a region of homology to an α1-3 galactosyltransferase genomic sequence. The cassettes can be employed to express foreign genes or to disrupt the native α1-3 galactosyltransferase genomic sequence, particularly within an animal. Thus, the invention also provides transgenic animals and methods for their production and use.

The invention discloses epimedium source galactosyl transferase and an application of the epimedium source galactosyl transferase to the preparation of hyperoside, and belongs to the technical field of gene engineering and biological medicines. The invention provides galactosyl transferase and an application of recombinant saccharomyces cerevisiae expressing the galactosyl transferase to the catalytic synthesis of flavonoid compounds. The constructed recombinant saccharomyces cerevisiae can be enabled to catalyze the transfer of UDP-galactose to various flavone substrates such as quercetin, kaempferol, myricetin, dihydroquercetin, dihydrokaempferol, dihydromyricetin, fisetin, morin and icaritin.

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.